Dermira Stock Price - DERM

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 10.16 ▲ 0.15 (1.50%)
Company Name Stock Ticker Symbol Market Type
Dermira Inc DERM NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.92 10.12% 10.01 10.98 9.56 9.67 9.09 00:00:04
Bid Price Ask Price Spread Spread % News
10.05 10.21 0.16 1.57% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
25,253 3,219,017 $ 9.98 $ 32,135,610 1,277,321 5.25 - 15.48
Last Trade Time Type Quantity Stock Price Currency
18:35:33 25 $ 10.16 USD

Dermira Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 545.76M 54.52M $ -221.54M -5.27 - 54.16M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 1.00 0.70%

more financials information »

Dermira News

Loading Messages....

Latest DERM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DERM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.9510.987.668.40967,4642.0625.91%
1 Month8.0510.987.408.21918,7981.9624.35%
3 Months8.9110.985.257.321,264,1951.1012.35%
6 Months10.2110.985.257.86914,674-0.20-1.96%
1 Year10.8815.485.259.811,161,596-0.87-8.0%
3 Years30.4938.755.2513.75833,400-20.48-67.17%
5 Years17.2138.755.2515.30562,096-7.20-41.84%

Dermira Description

Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.